AI-generated summary
The authors report a prospective before-after study of 2021 to 2023 in patients with moderate meibomian gland dysfunction and chronic ocular surface pain that did not respond to standard treatments. After three intense pulsed light sessions, pain scores and several tear film measures improved at two and four months. The study was monocentric and had no control group, so the findings are preliminary.
- Who or what was studied
- Patients with moderate meibomian gland dysfunction and chronic ocular surface pain unresponsive to conventional treatment, treated at a single center
- Limits stated in the abstract
- The abstract describes a monocentric before-after design without a control group, and the underlying mechanisms are stated to remain unexplored.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.